» Articles » PMID: 27443156

[Therapy of Fatigue in Multiple Sclerosis : A Treatment Algorithm]

Overview
Journal Nervenarzt
Specialty Neurology
Date 2016 Jul 23
PMID 27443156
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fatigue is one of the most frequent symptoms of multiple sclerosis (MS) and one of the main reasons for underemployment and early retirement. The mechanisms of MS-related fatigue are unknown but comorbid disorders play a major role. Anemia, diabetes, side effects of medication and depression should be ruled out. Moreover, excessive daytime sleepiness (EDS) should be differentiated from fatigue. No approved medicinal therapy of MS fatigue is currently available.

Objective: Presentation of current treatment strategies with a particular focus on secondary fatigue due to sleep disorders.

Material And Methods: A review of the literature was carried out.

Results And Conclusion: All MS patients suffering from fatigue should be questioned with respect to EDS and if necessary sleep medical investigations should be carried out; however, pure fatigue without accompanying EDS can also be caused by a sleep disorder. Medications, particularly freely available antihistamines, can also increase fatigue. Furthermore, anemia, iron deficits, diabetes and hypothyroidism should be excluded. Self-assessment questionnaires show an overlap between depression and fatigue. Several studies have shown that cognitive behavioral therapy and various psychotherapeutic measures, such as vertigo training, progressive exercise training and individualized physiotherapy as well as fatigue management interventions can lead to a significant improvement of MS-related fatigue. There is currently no medication which is suitable for treatment of fatigue, with the exception of fampridine for the treatment of motor functions and motor fatigue.

Citing Articles

Overview of the Current Pathophysiology of Fatigue in Multiple Sclerosis, Its Diagnosis and Treatment Options - Review Article.

Zimek D, Miklusova M, Mares J Neuropsychiatr Dis Treat. 2023; 19:2485-2497.

PMID: 38029042 PMC: 10674653. DOI: 10.2147/NDT.S429862.


The Effect of Coffee and Caffeine Consumption on Patients with Multiple Sclerosis-Related Fatigue.

Herden L, Weissert R Nutrients. 2020; 12(8).

PMID: 32731633 PMC: 7468779. DOI: 10.3390/nu12082262.


Evaluating the Effects of Dietary Interventions on Disease Progression and Symptoms of Adults with Multiple Sclerosis: An Umbrella Review.

Tredinnick A, Probst Y Adv Nutr. 2020; 11(6):1603-1615.

PMID: 32504530 PMC: 7666914. DOI: 10.1093/advances/nmaa063.


The Impact of Coffee and Caffeine on Multiple Sclerosis Compared to Other Neurodegenerative Diseases.

Herden L, Weissert R Front Nutr. 2019; 5:133.

PMID: 30622948 PMC: 6308803. DOI: 10.3389/fnut.2018.00133.


Fatigue as a symptom or comorbidity of neurological diseases.

Penner I, Paul F Nat Rev Neurol. 2017; 13(11):662-675.

PMID: 29027539 DOI: 10.1038/nrneurol.2017.117.


References
1.
Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L . Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. BMC Neurol. 2014; 14:220. PMC: 4253981. DOI: 10.1186/s12883-014-0220-1. View

2.
Mahajan S, Patel P, Marrie R . Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol. 2010; 183(4):1432-7. DOI: 10.1016/j.juro.2009.12.029. View

3.
Applebee A, Goodman A, Mayadev A, Bethoux F, Goldman M, Klingler M . Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial. Clin Ther. 2015; 37(12):2780-7. DOI: 10.1016/j.clinthera.2015.10.014. View

4.
Cote I, Trojan D, Kaminska M, Cardoso M, Benedetti A, Weiss D . Impact of sleep disorder treatment on fatigue in multiple sclerosis. Mult Scler. 2012; 19(4):480-9. DOI: 10.1177/1352458512455958. View

5.
Pucci E, Branas P, DAmico R, Giuliani G, Solari A, Taus C . Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007; (1):CD002818. PMC: 6991937. DOI: 10.1002/14651858.CD002818.pub2. View